GLP-1 Receptor Agonists
Semaglutide (Ozempic/Wegovy), Tirzepatide (Mounjaro/Zepbound)
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- FDA Approved (Wegovy 2021, Zepbound 2023)
Reference only. Not medical advice.
What can go wrong
Common adverse effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and dehydration, especially during dose escalation. Risks include pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumors based on rodent data (contraindicated with personal/family history of medullary thyroid carcinoma or MEN2). Rapid weight loss carries a lean-mass cost. Muscle and bone density should be monitored.
This is something to take to a clinician. The Atlas can tell you what is known about glp-1 receptor agonists in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
GLP-1 receptor agonists mimic the gut incretin hormone glucagon-like peptide-1, slowing gastric emptying, increasing satiety via hypothalamic signaling, and enhancing glucose-dependent insulin secretion. Semaglutide (a GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist) produce weight loss far beyond prior anti-obesity drugs. They are FDA-approved for type 2 diabetes and chronic weight management. Their relevance to men's sexual health is largely indirect, mediated through the metabolic and cardiovascular consequences of obesity.
The metabolic drug class that reshaped men's-health telehealth.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
GLP-1 is an incretin hormone released from intestinal L-cells after eating. Agonists bind GLP-1 receptors in the pancreas (glucose-dependent insulin release, suppressed glucagon), the gut (delayed gastric emptying), and the brain (reduced appetite and food reward via hypothalamic and brainstem circuits). Tirzepatide adds agonism at the GIP receptor, which appears to amplify weight loss and improve tolerability. The net effect is a large, sustained reduction in caloric intake.
What the men's-health marketing skips
GLP-1 drugs are not testosterone drugs and have no direct androgenic mechanism. Any benefit to male sexual health flows downstream from weight loss and metabolic improvement, not from a hormonal action on the testes. Effects also reverse: STEP 1 extension data showed participants regained roughly two-thirds of lost weight within a year of stopping, meaning metabolic and hormonal gains are contingent on continued use or maintained weight loss.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Weight and body composition
- HbA1c / glucose (in diabetics)
- Signs of pancreatitis or gallbladder disease
- Lean mass / muscle function during rapid loss
- Renal function with GI volume loss
What people get wrong
Often saidGLP-1 drugs directly raise testosterone
ActuallyThey have no direct androgenic mechanism. Observed testosterone increases in men are attributable to fat loss and improved insulin sensitivity, not a hormonal action of the drug.
Often saidThe benefits are permanent
ActuallyWeight regain after discontinuation is well documented (STEP 1 extension); metabolic gains are largely contingent on continued treatment or sustained weight loss.
Who profits, and who pushes back
Reproductive/andrology researchers
Argue that men's-health benefits are mostly indirect (driven by weight loss itself) and that direct effects on testosterone, sperm, and erectile function remain under-studied, with some safety signals warranting caution.
Skeptics of marketing extrapolation
Caution that small or short trials in healthy men show no hormonal benefit, so the testosterone and sexual-function claims should not be generalized beyond obese or diabetic men.
Evidence-quality reviewers
Note that much of the men's-health data is retrospective, observational, or from meeting abstracts, and cannot establish causation for the sexual-health outcomes being promoted.
Set against the alternatives
Compared with prior anti-obesity drugs (orlistat, phentermine, bupropion-naltrexone, which produced single-digit weight loss) GLP-1 agonists are a step change in efficacy. Within the class, tirzepatide's dual GIP/GLP-1 action generally outperforms semaglutide on weight loss in trials, while liraglutide (older, daily) is less potent than the weekly agents. Oral semaglutide offers a needle-free option but historically at lower exposures, and newer entrants such as triple agonists and amylin combinations report even larger losses in trials. For men's sexual health specifically, none of these agents has an approved sexual-function or testosterone indication; benefit, where seen, tracks the degree of metabolic improvement rather than a direct drug effect.
| Agent | Mechanism | Weight loss (trial) | Route |
|---|---|---|---|
| Semaglutide | GLP-1 | ~15% (STEP 1) | Weekly injection |
| Tirzepatide | GIP + GLP-1 | ~21% (SURMOUNT-1) | Weekly injection |
| Liraglutide | GLP-1 | ~8% (SCALE) | Daily injection |
| Oral semaglutide | GLP-1 | Lower, dose-dependent | Daily tablet |
| Retatrutide | GIP+GLP-1+glucagon | ~24-29% (trial) | Investigational |
What we do not know
- Do GLP-1 agonists improve erectile function and testosterone beyond what weight loss alone would predict?
- Are the reported sexual-health benefits durable, or do they regress with weight regain after discontinuation?
- What explains conflicting signals, with some datasets suggesting increased ED or testosterone-deficiency risk?
- How much of the lean-mass loss during rapid weight reduction matters for long-term sexual and metabolic health?
- Do dual and triple agonists differ from pure GLP-1 agents in male reproductive and hormonal outcomes?
What could change
Triple agonistsGLP-1/GIP/glucagon agents (e.g. retatrutide) reporting larger trial weight loss, pending FDA review.Amylin combinationsGLP-1 plus amylin combinations (e.g. CagriSema) advancing through late-stage trials.Oral non-peptidesSmall-molecule oral GLP-1 agonists (e.g. orforglipron) aiming for pill-based access at scale.Men's-health studiesDedicated prospective trials of testosterone, fertility, and erectile outcomes rather than retrospective extrapolation.
At a glance
- STEP 1 weight loss
- 14.9% at 68 wks (semaglutide 2.4mg)
- SURMOUNT-1 weight loss
- up to ~21% (tirzepatide 15mg)
- Dosing
- once-weekly subcutaneous injection
- Class
- GLP-1 (sema) / GIP+GLP-1 (tirz)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about GLP-1 Receptor Agonists. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
STEP 1 (Wilding et al., NEJM)2021
Semaglutide 2.4mg produced 14.9% mean weight loss vs 2.4% placebo at 68 weeks; 32% lost >=20% of body weight
SURMOUNT-1 (Jastreboff et al., NEJM)2022
Tirzepatide produced up to ~20.9% mean weight loss at the 15mg dose over 72 weeks
SELECT (Lincoff et al., NEJM)2023
In 17,604 adults with CVD and obesity but not diabetes, semaglutide cut major adverse cardiovascular events ~20%